Gilead secures first lenacapavir approval in Europe after lengthy manufacturing delays
Gilead is already a leader among biopharmas developing drugs to counteract HIV, and a new decision early Monday further cemented its place.
The European Commission has approved Gilead’s lenacapavir for adults with multi-drug resistant HIV, the company announced, giving the long-acting treatment its first green light. The drug, branded as Sunlenca on the continent, is designed to be administered once every six months.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.